SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gets EIR from USFDA for API manufacturing facility in Bangalore

09 May 2020 Evaluate

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at API manufacturing facility in Bommasandra, Bangalore. The agency had conducted inspection from January 20, 2020 to January 24, 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1453.20 -18.05 (-1.23%)
07-Jul-2026 15:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1902.70
Dr. Reddys Labs. 1356.90
Cipla 1453.20
Zydus Lifesciences 1152.40
Lupin 2492.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: